| 05th week of 2022 patent applcation highlights part 10 |
| Patent application number | Title | Published |
|---|
| 20220031658 | LASOFOXIFENE TREATMENT OF BREAST CANCER | 2022-02-03 |
| 20220031659 | NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE | 2022-02-03 |
| 20220031660 | CANCER TREATMENT COMPOSITION | 2022-02-03 |
| 20220031661 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | 2022-02-03 |
| 20220031662 | COMPOSITIONS COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR USE IN TREATING MENTAL DISORDERS | 2022-02-03 |
| 20220031663 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | 2022-02-03 |
| 20220031664 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIEMETICS AND ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USING THE SAME FOR ANESTHESIOLOGICAL APPLICATIONS | 2022-02-03 |
| 20220031665 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) NANO-FORMULATION OF COMPOUNDS AND METHODS OF USING THE SAME | 2022-02-03 |
| 20220031666 | PPARo ACTIVATOR | 2022-02-03 |
| 20220031667 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | 2022-02-03 |
| 20220031668 | METHODS OF INHIBITING PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 2 | 2022-02-03 |
| 20220031669 | Compositions for Broad Spectrum Topical Antimicrobials | 2022-02-03 |
| 20220031670 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | 2022-02-03 |
| 20220031671 | TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND | 2022-02-03 |
| 20220031672 | DISCOVERY OF NOVEL ANTI-INFECTIVES FOR GRAM NEGATIVE PATHOGENS | 2022-02-03 |
| 20220031673 | Novel Compositions and Methods for Treating or Preventing Dermal Disorders | 2022-02-03 |
| 20220031674 | COMPOSITIONS AND METHODS FOR TREATING CANCER | 2022-02-03 |
| 20220031675 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | 2022-02-03 |
| 20220031676 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | 2022-02-03 |
| 20220031677 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF | 2022-02-03 |
| 20220031678 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHY- RIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | 2022-02-03 |
| 20220031679 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF | 2022-02-03 |
| 20220031680 | Donecopride As Neuroprotective Agent In the Treatment of Neurodegenerative Diseases | 2022-02-03 |
| 20220031681 | Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones | 2022-02-03 |
| 20220031682 | SPHINGOSINE KINASE 2 INHIBITOR FOR TREATING CORONAVIRUS INFECTION | 2022-02-03 |
| 20220031683 | COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION | 2022-02-03 |
| 20220031684 | PROPHYLACTIC EFFICACY OF SEROTONIN 4 RECEPTOR AGONISTS AGAINST STRESS | 2022-02-03 |
| 20220031685 | COMBINATION THERAPY FOR TREATING BLOOD CANCER | 2022-02-03 |
| 20220031686 | Treatment of Migraine | 2022-02-03 |
| 20220031687 | SYNERGIC PHARMACEUTICAL COMBINATION OF A LEUKOTRIENE-RECEPTOR ANTAGONIST AND AN INVERSE AGONIST OF HISTAMINE HI | 2022-02-03 |
| 20220031688 | C-Met Modulator Pharmaceutical Compositions | 2022-02-03 |
| 20220031689 | QUINOLINE DERIVATIVE USED FOR TREATING SMALL CELL LUNG CANCER | 2022-02-03 |
| 20220031690 | ANTI-NEURODEGENERATIVE DISEASE AGENT | 2022-02-03 |
| 20220031691 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | 2022-02-03 |
| 20220031692 | BUPRENORPHINE DOSING REGIMENS | 2022-02-03 |
| 20220031693 | Tamper Resistant Immediate Release Formulations | 2022-02-03 |
| 20220031694 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND MDM2 INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | 2022-02-03 |
| 20220031695 | SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER | 2022-02-03 |
| 20220031696 | ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3 | 2022-02-03 |
| 20220031697 | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors | 2022-02-03 |
| 20220031698 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | 2022-02-03 |
| 20220031699 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS | 2022-02-03 |
| 20220031700 | Treatment of Acute Respiratory Distress Syndrome (ARDS) | 2022-02-03 |
| 20220031701 | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH UNCONTROLLED INFLAMMATORY RESPONSES | 2022-02-03 |
| 20220031702 | Solid Pharmaceutical Formulation of PARP Inhibitors and Use Thereof | 2022-02-03 |
| 20220031703 | SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING BIOPTERIN DERIVATIVES AND USES OF SUCH COMPOSITIONS | 2022-02-03 |
| 20220031704 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | 2022-02-03 |
| 20220031705 | LAURETH-4 CONTAINING TOPICAL FORMULATIONS | 2022-02-03 |
| 20220031706 | TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY | 2022-02-03 |
| 20220031707 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING AT LEAST ONE LOCAL ANAESTHETIC SUBSTANCE | 2022-02-03 |
| 20220031708 | METHOD FOR TREATING IDIOPATHIC PULMONARY FIBROSIS | 2022-02-03 |
| 20220031709 | INHIBITION OF MICROSOMAL PROSTAGLANDIN E2 (PGE2) SYNTHASE-1 (MPGES-1) | 2022-02-03 |
| 20220031710 | USE OF ERK5 INHIBITORS FOR TREATING GLIOMAS IN PEDIATRIC SUBJECTS | 2022-02-03 |
| 20220031711 | Methods for Attenuating Graft-Versus-Host Disease and Opportunistic Infections | 2022-02-03 |
| 20220031712 | PREPARATION OF A PHARMACEUTICAL COMPOSITION OF OLODATEROL AND BUDESONIDE | 2022-02-03 |
| 20220031713 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS | 2022-02-03 |
| 20220031714 | MODIFIED RELEASE DOXYCYCLINE COMPOSITION | 2022-02-03 |
| 20220031715 | COMPOSITIONS AND METHODS FOR ENHANCING WOUND HEALING | 2022-02-03 |
| 20220031716 | CONDITIONING REGIMENS AND METHODS FOR INDUCING MIXED CHIMERISM | 2022-02-03 |
| 20220031717 | LIPID COMPOSITION COMPRISING ANTIOXIDANTS AND NATURAL POLYPHENOLS AS A NON-PHARMACOLOGICAL ALTERNATIVE FOR THE TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) | 2022-02-03 |
| 20220031718 | GLUCOSE INFUSION SOLUTION COMPOSITION | 2022-02-03 |
| 20220031719 | ANTIVIRAL THERAPEUTIC DRUG COMBINATIONS | 2022-02-03 |
| 20220031720 | IMMUNOGENIC COMPOSITIONS CONTAINING N-GLYCOL YLNEURAMINIC ACID BEARING NANOPARTICLES | 2022-02-03 |
| 20220031721 | SKIN BARRIER COMPOSITION | 2022-02-03 |
| 20220031722 | COMBINATION THERAPY | 2022-02-03 |
| 20220031723 | POWDERED FOOD COMPOSITION COMPRISING ERIOCITRIN | 2022-02-03 |
| 20220031724 | INJECTABLE ANTIBIOTIC FORMULATIONS AND USE THEREOF | 2022-02-03 |
| 20220031725 | TREATMENT OF AGING-ASSOCIATED CONDITIONS BY DNA DEGRADATION | 2022-02-03 |
| 20220031726 | NOVEL COMBINATION TREATMENT FOR ACUTE MYELOID LEUKEMIA (AML) | 2022-02-03 |
| 20220031727 | FORMULATION COMPRISING A GEMCITABINE-PRODRUG | 2022-02-03 |
| 20220031728 | FORMULATIONS OF PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE DRUGS | 2022-02-03 |
| 20220031729 | USE OF S-ADENOSYLMETHIONINE FOR PERSONALIZED TREATMENT OF DEPRESSION | 2022-02-03 |
| 20220031730 | ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION | 2022-02-03 |
| 20220031731 | COMPOSITIONS AND METHODS FOR MODULATION OF LMNA EXPRESSION | 2022-02-03 |
| 20220031732 | A Composition for Use in the Prevention and/or Treatment of Epistaxis | 2022-02-03 |
| 20220031733 | COMPOSITION FOR THE TREATMENT OF THE ORAL CAVITY | 2022-02-03 |
| 20220031734 | Medical Device Comprising Boswellic Acid | 2022-02-03 |
| 20220031735 | INTRADIALYTIC USE OF SODIUM THIOSULFATE | 2022-02-03 |
| 20220031736 | USE OF ANIONIC CLAY IN PREPARING LEAD-REMOVING MEDICINE | 2022-02-03 |
| 20220031737 | PHARMACEUTICAL COMPOSITIONS COMPRISING CHROMIUM AND CARBOHYDRATE BLOCKERS | 2022-02-03 |
| 20220031738 | IRON FORMULATIONS FOR TOPICAL ADMINISTRATION AND METHODS OF TREATMENT OF IRON DEFICIENCY | 2022-02-03 |
| 20220031739 | ANTI-VIRAL COMPOSITIONS AND METHODS OF USE THEREOF | 2022-02-03 |
| 20220031740 | THERAPEUTIC USES OF ATOMIC QUANTUM CLUSTERS | 2022-02-03 |
| 20220031741 | METHODS AND REAGENTS FOR MODULATING MACROPHAGE PHENOTYPE | 2022-02-03 |
| 20220031742 | CHIMERIC ANTIGEN RECEPTOR THAT BINDS HLA-DR AND CAR-T CELL | 2022-02-03 |
| 20220031743 | TRANSPLANTATION OF MITOCHONDRIA INTO LYMPHOID ORGAN AND COMPOSITION THEREFOR | 2022-02-03 |
| 20220031744 | PROTEIN L FOR ACTIVATION AND EXPANSION OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED IMMUNE CELLS | 2022-02-03 |
| 20220031745 | ANTIGEN DENSITY SENSING MOLECULAR CIRCUITS AND METHODS OF USE THEREOF | 2022-02-03 |
| 20220031746 | METHODS FOR DOSING AND TREATMENT OF B CELL MALIGNANCIES IN ADOPTIVE CELL THERAPY | 2022-02-03 |
| 20220031747 | FOXP1-ABLATED CHIMERIC CELLS | 2022-02-03 |
| 20220031748 | COMPOSITIONS AND METHODS FOR TREATING CANCER | 2022-02-03 |
| 20220031749 | MULTIPLEX GENOME EDITING OF IMMUNE CELLS TO ENHANCE FUNCTIONALITY AND RESISTANCE TO SUPPRESSIVE ENVIRONMENT | 2022-02-03 |
| 20220031750 | DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES | 2022-02-03 |
| 20220031751 | METHODS OF PRODUCING T REGULATORY CELLS, METHODS OF TRANSDUCING T CELLS, AND USES OF THE SAME | 2022-02-03 |
| 20220031752 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof | 2022-02-03 |
| 20220031753 | T CELL RECEPTORS | 2022-02-03 |
| 20220031754 | CELLS COMPRISING NON-HLA RESTRICTED T CELL RECEPTORS | 2022-02-03 |
| 20220031755 | BIOACTIVE RENAL CELLS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE | 2022-02-03 |
| 20220031756 | Stem Cells for Wound Healing | 2022-02-03 |
| 20220031757 | METHOD FOR REPAIRING DAMAGED TISSUE | 2022-02-03 |
